ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 3,312 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 3,312 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.00, for a total value of $264,960.00. Following the transaction, the chief financial officer owned 180,393 shares of the company’s stock, valued at approximately $14,431,440. This represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP traded up $1.07 during midday trading on Tuesday, hitting $81.20. 271,945 shares of the company’s stock were exchanged, compared to its average volume of 399,089. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The stock’s 50 day moving average price is $79.18 and its 200-day moving average price is $79.36. The firm has a market cap of $1.85 billion, a P/E ratio of 20.56 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a twelve month low of $61.17 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. KBC Group NV purchased a new stake in ANI Pharmaceuticals during the first quarter valued at about $28,000. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth approximately $28,000. Hantz Financial Services Inc. raised its holdings in shares of ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 237 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ANIP shares. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.